long intergenic non-protein coding RNA 504Genealiases: []
Q-omics provides the consensus-scored LINC00504 profile across patient tissues and cancer cell-line models. LINC00504 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC00504 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, LINC00504 RNA expression shows 14,267 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where LINC00504 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00504 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00504 survival associations across molecular data types. LINC00504 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00504 RNA expression–survival associations across cancer types. High LINC00504 expression shows unfavorable associations in BLCA, LGG and LAML, but favorable associations in KIRC, LIHC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC00504 RNA expression.
This table summarizes LINC00504 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00504. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00504 shows lower tumor expression in LUAD and UCEC and higher tumor expression in HNSC, BRCA, LUSC and LIHC. The HNSC box plot shows higher LINC00504 RNA expression in tumor versus normal tissue (log2 FC = +0.881, t-test p < 0.001).
This table shows molecular features associated with LINC00504 in patient tissues and cancer cell lines. In patient samples, LINC00504 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC00504 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY.
